Correction of previous press release
(Thomson Reuters ONE) -
In the English version of the press release "Sobi holds Capital Markets Seminar"
dated 29 November, 2011, the gross margin for the Specialty Distribution
Portfolio was incorrectly stated as <40%. The correct figure is <50%, see table
below. The Swedish version of the press release was correct.
+--------------------------------+--------+------+---------------+
|Product area |Revenues|Growth|Gross margin, %|
+--------------------------------+--------+------+---------------+
|ReFacto® | 608| 34%| >60%|
+--------------------------------+--------+------+---------------+
|Core Products | 803| 6%| ~60%|
+--------------------------------+--------+------+---------------+
|Specialty Distribution Portfolio| 459| 8%| <50%|
+--------------------------------+--------+------+---------------+
Revenues are rolling 12 months as of 30 September 2011 in reported exchange
rates, adjusted for discontinued products. Growth figures are based on YTD 9
months 2011, adjusted for currency and discontinued products.
For further information, please contact:
Åsa Stenqvist, Head of Communications and Investor Relations
Tel.: +46 8 697 21 88
Swedish Orphan Biovitrum (Sobi)
Sobi is a leading integrated biopharmaceutical company dedicated to bringing
innovative therapies and services to improve the health of rare disease patients
and their families. The product portfolio comprises about 60 marketed products
as well as projects in the late clinical phase. Key therapeutic areas are
Inflammation and Genetics & Metabolism. In 2010 Sobi had revenues of SEK 1.9
billion and around 500 employees. The share (STO: SOBI) is listed on OMX NASDAQ
Stockholm. More information is available atwww.sobi.com.
The information above has been published pursuant to the Swedish Securities
Market Act and/or the Financial Instruments Trading Act. The information was
released for public distribution on 1 December 2011 at 12.30 CET.
Press release correction Dec 1, 2011:
http://hugin.info/134557/R/1568101/487320.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE
[HUG#1568101]
Unternehmensinformation / Kurzprofil:
Datum: 01.12.2011 - 12:34 Uhr
Sprache: Deutsch
News-ID 93113
Anzahl Zeichen: 2979
contact information:
Town:
Stockholm
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 115 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Correction of previous press release"
steht unter der journalistisch-redaktionellen Verantwortung von
Swedish Orphan Biovitrum AB (publ) (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
